CCL2 and glomerulosclerosis: Han et al. showed that spironolactone reduces albuminuria, inflammation and glomerulosclerosis in diabetic rats, and that it inhibits nuclear factor-κB (NF-κB) activation and monocyte chemoattractant protein-1 (MCP-1) production in cultured intrinsic renal cells [68].